CAMP4 Therapeutics, a clinical-stage biotech developing RNA-based therapies to target genetic diseases, raised $75 million by offering 6.8 million shares at $11, below the range of $14 to $16. The Cambridge, MA-based company sold 1.8 million more shares than planned n order to keep the deal size at the original target of $75 million.
CAMP4 Therapeutics is developing regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. It is developing a proprietary RNA Actuating Platform to identify and characterize the active regulatory elements controlling expressed genes. CAMP4 Therapeutics is initially focused on metabolic and central nervous system, or CNS, diseases. Its lead candidate is in a Phase 1 trial for urea cycle disorders, and expects data in 2025.
CAMP4 Therapeutics plans to list on the Nasdaq under the symbol CAMP. J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair acted as joint bookrunners on the deal.
